US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

0.2660

-0.1300-32.83%

Post-market: 0.2611-0.0049-1.84%19:54 EDT

Volume:543.41K

Turnover:163.48K

Market Cap:4.42M

PE:-0.06

High:0.3900

Open:0.3700

Low:0.2605

Close:0.3960

Loading ...

Overview Company News Filings

Super League Enterprise Inc Files for Offering of up to 3.03 Mln Common Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

TNXP: NDA Filed for TNX-102 SL in Fibromyalgia…

Zacks Small Cap Research

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?

Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%

Press Release: Fate Therapeutics Announces Leadership Transition

BRIEF-Super League Enterprise Issues Unsecured Promissory Note For $1.5 Million

Super League Enterprise Inc - Issues Unsecured Promissory Note for $1.5 Million

THOMSON REUTERS

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

Super League Enterprise price target lowered to $2 from $3 at H.C. Wainwright

Super League Enterprise, Inc. : H.c. Wainwright Cuts Target Price to $2 From $3

THOMSON REUTERS

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/SLE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.266,"timestamp":1743192000000,"preClose":0.396,"halted":0,"volume":543407,"hourTrading":{"tag":"盘后","latestPrice":0.2611,"preClose":0.266,"latestTime":"19:54 EDT","volume":22763,"amount":6039.5941,"timestamp":1743206064403},"delay":0,"floatShares":11261099,"shares":16604900,"eps":-4.481745,"marketStatus":"Market Closed","change":-0.13,"latestTime":"03-28 16:00:00 EDT","open":0.37,"high":0.39,"low":0.2605,"amount":163477.76307170998,"amplitude":0.32702,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.481745,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.396,"preHourTrading":{"tag":"盘前","latestPrice":0.3679,"preClose":0.396,"latestTime":"09:29 EDT","volume":37410,"amount":13575.103994699999,"timestamp":1743168560121},"postHourTrading":{"tag":"盘后","latestPrice":0.2611,"preClose":0.266,"latestTime":"19:54 EDT","volume":22763,"amount":6039.5941,"timestamp":1743206064403},"volumeRatio":3.0869329113584714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":11261099,"roa":"-54.85%","roe":"-244.57%","lyrEps":-13.672882,"volumeRatio":3.0869329113584714,"shares":16604900,"dividePrice":0,"high":0.39,"amplitude":0.32702,"preClose":0.396,"low":0.2605,"week52Low":0.2605,"pbRate":"1.26","psRate":"0.20","week52High":2.38,"institutionHeld":0,"latestPrice":0.266,"eps":-4.481745,"divideRate":0,"volume":543407,"delay":0,"ttmEps":-4.481745,"open":0.37,"prevYearClose":0.6175,"prevWeekClose":0.368,"prevMonthClose":0.381,"prevQuarterClose":0.6175,"fiveDayClose":0.368,"twentyDayClose":0.381,"sixtyDayClose":0.6312},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:16,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2489428890","title":"Super League Enterprise Inc Files for Offering of up to 3.03 Mln Common Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2489428890","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489428890?lang=en_us&edition=fundamental","pubTime":"2024-12-06 19:17","pubTimestamp":1733483825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N61G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2489143140","title":"Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2489143140","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489143140?lang=en_us&edition=fundamental","pubTime":"2024-12-05 19:01","pubTimestamp":1733396460,"startTime":"0","endTime":"0","summary":"Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/05/2992165/0/en/Nkarta-Announces-IND-Clearance-of-Investigator-Sponsored-Trial-in-Myasthenia-Gravis-and-Opening-of-Enrollment-for-Ntrust-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","CAR","UCI","BK4077","BK4546","IE00B7SZL793.SGD","SLE","BK4230","IMNM","BK4505","BK4139","IE00B66KJ199.SGD","IE0031619046.USD","MG","DM","BK4022","NKTX","BK4161","IE00B19Z4B17.USD","BK4563"],"gpt_icon":0},{"id":"2488094266","title":"TNXP: NDA Filed for TNX-102 SL in Fibromyalgia…","url":"https://stock-news.laohu8.com/highlight/detail?id=2488094266","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488094266?lang=en_us&edition=fundamental","pubTime":"2024-12-03 18:25","pubTimestamp":1733221500,"startTime":"0","endTime":"0","summary":"On October 16, 2024, Tonix Pharmaceuticals Holding Corp.  announced that it had filed the New Drug Application  for TNX-102 SL for the treatment of fibromyalgia. The FDA typically has a 60-day window to determine if the submitted NDA is acceptable for review. If accepted, the FDA will issue a Prescription Drug User Fee Act  date for a decision on approval, which we anticipate being in August 2025 for a standard review or April 2025 for priority review. TNX-102 SL was previously granted Fast Track designation by the FDA in July 2024, making it eligible for priority review, however that is not determined by the FDA until acceptance of the NDA.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KUgYeMEXwVPR9UEOpfbqJg--~B/aD03ODg7dz0xMzk2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/f0d0fa1979251d8fabfe1285ca18a24e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KUgYeMEXwVPR9UEOpfbqJg--~B/aD03ODg7dz0xMzk2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/f0d0fa1979251d8fabfe1285ca18a24e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnxp-nda-filed-tnx-102-102500471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0261945553.USD","SG9999013478.USD","LU0048573645.USD","SGXZ58947870.SGD","LU0109394709.USD","IE0034224299.USD","LU0234570918.USD","SG9999005177.SGD","IE00B19Z9Z06.USD","BK4085","LU0210637038.USD","IE00B19Z9P08.USD","LU0532188223.SGD","SG9999006266.SGD","BK4585","SG9999002620.SGD","BK4532","LU2125910500.SGD","BK4077","IE00B894F039.SGD","LU0251143029.SGD","SG9999002604.SGD","BK4535","BK4583","SG9999001135.SGD","BIIB","BK4566","BK4139","SG9999002406.SGD","BK4503","LU0889565916.HKD","BK4551","LU0320765992.SGD","SG9999002679.SGD","SG9999002414.USD","SG9999013460.SGD","SG9999013486.USD","BK4554","LU2045819591.USD","BK4533","BK4581","SLE","TNXP","LU0737861269.HKD","BK4588","SG9999014484.SGD","SG9999004360.SGD","BK4548","SG9999014492.USD"],"gpt_icon":1},{"id":"2488957588","title":"Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2488957588","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488957588?lang=en_us&edition=fundamental","pubTime":"2024-12-03 02:19","pubTimestamp":1733163540,"startTime":"0","endTime":"0","summary":"Shares of Allogene Therapeutics ALLO have lost nearly 23% year to date, underperforming the industry’s 7.0% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. ALLO’s shares are trading below the 50 and 200-day moving averages.ALLO Stock Underperforms Industry, Sector & S&P 500. The decline in stock price can be attributed to the strategic changes in Allogene’s pipeline, announced at the start of this year. This delayed management’s plans to bring cema-cel, its lead pipeline drug, to the market by at least a couple of years.Let’s dig into the stock’s prospects.ALLO Explores Lead Drug’s Potential as First-Line LBCL Therapy. Allogene is also planning to explore the potential of allogeneic CAR-T cell therapies in autoimmune diseases. In this regard, it plans to start an early-stage study with a new candidate, ALLO-329, in lupus/systemic lupus erythematosus  indication by first-quarter 2025 and expects to have proof-of-","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-loses-23-date-181900263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","RCC","SLE","ALLO","BK4505","CSTL","LENZ","SPRO","BK4139","BK4077"],"gpt_icon":0},{"id":"2488710036","title":"Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2488710036","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488710036?lang=en_us&edition=fundamental","pubTime":"2024-12-02 22:00","pubTimestamp":1733148000,"startTime":"0","endTime":"0","summary":"Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including sy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/02/2989864/0/en/Sana-Biotechnology-Announces-Fast-Track-Designation-for-SC291-in-Relapsed-Refractory-Systemic-Lupus-Erythematosus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4022","SANA","BK4230","SLE","BK4077","CAR","FAST"],"gpt_icon":0},{"id":"2487522078","title":"Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487522078","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487522078?lang=en_us&edition=fundamental","pubTime":"2024-11-30 16:35","pubTimestamp":1732955700,"startTime":"0","endTime":"0","summary":"Cathie Wood is known for investing in innovators working on game-changing technology.This top investor focuses on choosing quality companies and sticking with them for the long term.This particular stock is one of Wood’s favorites -- and the company launched its first product earlier this year.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799256%2Finvestor-smiling-computer.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799256%2Finvestor-smiling-computer.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/11/30/meet-the-beaten-down-stock-cathie-wood-loves/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CRSP","LU1069344957.HKD","BK4585","VRTX","IE00B19Z3581.USD","LU0256863811.USD","LU1093756168.USD","LU2456880835.USD","LU0889565916.HKD","LU0061475181.USD","IE00BJJMRZ35.SGD","IE00B19Z9Z06.USD","LU1861559042.SGD","IE0009355771.USD","LU2362541513.USD","SLE","BK4139","BK4556","IE00B894F039.SGD","LU2462157665.USD","ARKK","LU1093756325.SGD","LU2236285917.USD","IE0002141913.USD","LU0289739699.SGD","LU1035775433.USD","VERX","LU2362540622.SGD","BK4567","LU1585245621.USD","LU0823416689.USD","IE00BJT1NW94.SGD","BK4532","IE00B2B36J28.USD","BK4544","LU0234570918.USD","LU0079474960.USD","LU0109394709.USD","LU2324357040.USD","LU2417539215.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","IE0002270589.USD","IE00B4R5TH58.HKD","LU0417517546.SGD","BK4533","LU2237438978.USD","LU1861558580.USD","LU2362541273.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2487110598","title":"Press Release: Fate Therapeutics Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2487110598","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487110598?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:05","pubTimestamp":1732903500,"startTime":"0","endTime":"0","summary":"Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025. Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies. SAN DIEGO, Nov. 29, 2024  -- Fate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell -derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Valamehr, Ph.D. MBA, will assume the role of President and CEO as of January 1, 2025. Fate Therapeutics will passionately continue its mission to develop novel off-the-shelf cellular immunotherapies to broadly treat patients in need.Included in the Company's product candidate pipeline is FT819, the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","FATE","BK4077","BK4139"],"gpt_icon":0},{"id":"2485498488","title":"BRIEF-Super League Enterprise Issues Unsecured Promissory Note For $1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498488?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:46","pubTimestamp":1732193173,"startTime":"0","endTime":"0","summary":"Nov 21 (Reuters) - Super League Enterprise Inc   :   * SUPER LEAGUE ENTERPRISE INC - ISSUES UNSECURED PROMISSORY NOTE FOR $1.5 MILLIONSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2485498160","title":"Super League Enterprise Inc - Issues Unsecured Promissory Note for $1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498160","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498160?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:45","pubTimestamp":1732193140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS0NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2485129271","title":"Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2485129271","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485129271?lang=en_us&edition=fundamental","pubTime":"2024-11-21 02:32","pubTimestamp":1732127549,"startTime":"0","endTime":"0","summary":"On Tuesday, UCB SA   andBiogen Inc.  presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol  for systemic lupus erythematosus.The drug candidate demonstrated significant clinical improvement in disease activity in patients with moderate-to-severe systemic lupus erythematosus .Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial. The results were shared at the American College of Rheumatology’s annual meeting. In the 321-subject trial, DZP was administered intravenously every four weeks.On the primary endpoint measuring improvement of moderate-to-severe disease activity after 48 weeks, study participants receiving DZP plus standard care had a statistically significant 14.6% higher response rate  than those receiving SOC alone .On the first secondary endpoint of disease activity response at Week 24, study participants receiving DZP plus SOC had a 7.9% higher response rate","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g_o1nay57O4ZIDCyVLelXw--~B/aD00OTg7dz04ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/3de241384d40b386a866beb16813a4d2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g_o1nay57O4ZIDCyVLelXw--~B/aD00OTg7dz04ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/3de241384d40b386a866beb16813a4d2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-gains-momentum-positive-lupus-183229256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B894F039.SGD","LU0889565916.HKD","BK4532","UCBJF","UCBJY","IE00B19Z9P08.USD","BK4585","BK4533","BK4139","BK4588","IE00B19Z9Z06.USD","BK4077","BIIB","LU0109394709.USD","LU0320765992.SGD","SLE","LU0234570918.USD"],"gpt_icon":0},{"id":"2485914405","title":"CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485914405","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485914405?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:21","pubTimestamp":1732112460,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics’ CRSP shares have lost 6.6% in the past two weeks compared with the industry’s 8.4% decline, as seen in the chart below. The stock has underperformed the sector and the S&P 500 index. Shares of the company are also currently trading below its 50-day and 200-day moving averages.Approval for First CRISPR-Based Therapy: A Boon for CRSP Stock. This approval was a breakthrough for medical science, as it was the first for a CRISPR-based gene-editing therapy. Both SCD and TDT indications have a significant unmet medical need. Casgevy has the potential to alleviate blood transfusion requirements for TDT patients and reduce painful and debilitating sickle crises for SCD patients. Per management, the therapy offers a new treatment option to nearly 35,000 patients living with severe SCD or TDT across the United States and Europe, with additional patients in Bahrain and Saudi Arabia.CRISPR Therapeutics is yet to record collaboration revenues from Vertex for Casgevy sales.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-stock-falls-7-142100045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0417517546.SGD","LU0109394709.USD","LU1585245621.USD","LU2456880835.USD","SCD","LU2362541273.HKD","BEAM","IE0002270589.USD","LU1093756325.SGD","IE00B19Z3B42.SGD","BK4505","VRTX","LU0256863811.USD","BK4077","LU1861559042.SGD","IE00BJJMRZ35.SGD","BK4535","LU2462157665.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU2237438978.USD","LU0061475181.USD","LU1035775433.USD","IE00B19Z9P08.USD","LU0889565916.HKD","LENZ","LU1069344957.HKD","LU2236285917.USD","BK4556","BK4533","IE00B19Z9Z06.USD","LU0079474960.USD","IE00BFTCPJ56.SGD","BK4585","SLE","BK4532","BK4139","LU1430594728.SGD","LU2417539215.USD","EDIT","CRSP","LU0058720904.USD","BK4588","IE00B2B36J28.USD","LU0320765992.SGD","IE0009355771.USD","BK4567","LU2362541513.USD","IE00B4R5TH58.HKD","LU1093756168.USD"],"gpt_icon":0},{"id":"2484329199","title":"Super League Enterprise price target lowered to $2 from $3 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2484329199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484329199?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:11","pubTimestamp":1732101087,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Super League Enterprise (SLE) to $2 from $3 and keeps a Buy rating on the shares following the Q...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-price-target-lowered-to-2-from-3-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-price-target-lowered-to-2-from-3-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2484196503","title":"Super League Enterprise, Inc. : H.c. Wainwright Cuts Target Price to $2 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2484196503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484196503?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:01","pubTimestamp":1732100511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nAZN2NDTWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2484903430","title":"FATE Presents Encourgaing Data From Lupus Study, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903430","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903430?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:55","pubTimestamp":1732042500,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819.Data showed that the first patient suffering from active lupus nephritis  and treated with FT819 had favorable clinical experience, achieved drug-free clinical remission and continued on-study free of all immunosuppressive therapy.Shares of Fate have lost 42.8% year to date compared with the industry’s decline of 11.1%.FT819 is FATE’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The initial results are promising, and FATE believes this differentiated therapeutic approach has the potential to transform outcomes for patients with autoimmune diseases without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy and extended hospital","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMCR","CSTL","BK4505","BK4077","SLE","SPRO","FATE","BK4196","BK4139"],"gpt_icon":0},{"id":"2484562620","title":"Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484562620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484562620?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936600,"startTime":"0","endTime":"0","summary":"ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine ModelsProprietary Dagger Technology Enables ALLO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982777/0/en/Allogene-Therapeutics-Presents-Preclinical-Data-for-ALLO-329-an-Allogeneic-CD19-CD70-Dual-CAR-T-for-the-Treatment-of-Autoimmune-Disease-at-the-American-College-of-Rheumatology-ACR-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","BK4149","BK4139","BK4230","BK4505","SLE","BK4077","BK4022","BK4112","BK4117","CAR","BK4110","TRAC","AFG","MLR","ALLO","ACR"],"gpt_icon":0},{"id":"2484622908","title":"Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622908?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:05","pubTimestamp":1731935100,"startTime":"0","endTime":"0","summary":"27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Pat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982757/24675/en/Fate-Therapeutics-Presents-6-Month-Follow-up-Data-on-First-Patient-Treated-in-Phase-1-Autoimmunity-Study-with-Fludarabine-free-Conditioning-and-FT819-Off-the-shelf-1XX-CAR-T-cell-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","ACR","BK4230","FATE","IE0031619046.USD","BK4110","BK4139","LU2463526074.USD","IE00B19Z4B17.USD","CRS","SLE","BK4077","BK4022","IE00B7SZL793.SGD","BK4006","IE00B66KJ199.SGD","CAR","ASH"],"gpt_icon":1}],"pageSize":16,"totalPage":9,"pageCount":4,"totalSize":131}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-3.47},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2024-05-15","symbol":"SLE","fiscalQuarterEnding":"2024/03","expectedEps":-1.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2024-03-27","symbol":"SLE","fiscalQuarterEnding":"2023/12","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711512000000,"reportTimeType":"post","actualEps":-3.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-03-28","current":-0.230354,"percent":0.696133,"low":-0.555206,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"high":-0.044016,"avg":-0.276106,"sd":0.108282,"marketCap":5671557},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557}],"updateTime":1743237851187}}}